vs
吉利德科学（GILD）与RYDER SYSTEM INC（R）财务数据对比。点击上方公司名可切换其他公司
RYDER SYSTEM INC的季度营收约是吉利德科学的1.7倍（$13.1B vs $7.9B），吉利德科学净利率更高（27.5% vs 0.7%，领先26.8%），吉利德科学同比增速更快（4.7% vs 1.0%），吉利德科学自由现金流更多（$3.1B vs $273.0M），过去两年RYDER SYSTEM INC的营收复合增速更高（102.9% vs 8.9%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
Ryder System Inc.是美国专业运输物流服务商，总部位于佛罗里达州科勒尔盖布尔斯，业务覆盖美国及英国，核心业务包含卡车租赁、车队管理、供应链及运输管理，同时提供车辆维保、二手车销售、专业司机派遣、电商履约与最后一公里配送等多元服务。
GILD vs R — 直观对比
营收规模更大
R
是对方的1.7倍
$7.9B
营收增速更快
GILD
高出3.7%
1.0%
净利率更高
GILD
高出26.8%
0.7%
自由现金流更多
GILD
多$2.8B
$273.0M
两年增速更快
R
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $13.1B |
| 净利润 | $2.2B | $93.0M |
| 毛利率 | 79.5% | — |
| 营业利润率 | 25.0% | — |
| 净利率 | 27.5% | 0.7% |
| 营收同比 | 4.7% | 1.0% |
| 净利润同比 | 22.4% | -5.1% |
| 每股收益（稀释后） | $1.75 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDR
| Q1 26 | — | $13.1B | ||
| Q4 25 | $7.9B | $3.2B | ||
| Q3 25 | $7.8B | $3.2B | ||
| Q2 25 | $7.1B | $3.2B | ||
| Q1 25 | $6.7B | $3.1B | ||
| Q4 24 | $7.6B | $3.2B | ||
| Q3 24 | $7.5B | $3.2B | ||
| Q2 24 | $7.0B | $3.2B |
净利润GILDR
| Q1 26 | — | $93.0M | ||
| Q4 25 | $2.2B | $132.0M | ||
| Q3 25 | $3.1B | $138.0M | ||
| Q2 25 | $2.0B | $131.0M | ||
| Q1 25 | $1.3B | $98.0M | ||
| Q4 24 | $1.8B | $135.0M | ||
| Q3 24 | $1.3B | $142.0M | ||
| Q2 24 | $1.6B | $127.0M |
毛利率GILDR
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率GILDR
| Q1 26 | — | — | ||
| Q4 25 | 25.0% | 5.6% | ||
| Q3 25 | 42.8% | 6.0% | ||
| Q2 25 | 34.9% | 5.8% | ||
| Q1 25 | 33.6% | 4.3% | ||
| Q4 24 | 32.4% | 5.7% | ||
| Q3 24 | 11.8% | 5.9% | ||
| Q2 24 | 38.0% | 5.6% |
净利率GILDR
| Q1 26 | — | 0.7% | ||
| Q4 25 | 27.5% | 4.2% | ||
| Q3 25 | 39.3% | 4.4% | ||
| Q2 25 | 27.7% | 4.1% | ||
| Q1 25 | 19.7% | 3.1% | ||
| Q4 24 | 23.6% | 4.2% | ||
| Q3 24 | 16.6% | 4.5% | ||
| Q2 24 | 23.2% | 4.0% |
每股收益（稀释后）GILDR
| Q1 26 | — | $2.34 | ||
| Q4 25 | $1.75 | $3.22 | ||
| Q3 25 | $2.43 | $3.32 | ||
| Q2 25 | $1.56 | $3.13 | ||
| Q1 25 | $1.04 | $2.27 | ||
| Q4 24 | $1.43 | $3.09 | ||
| Q3 24 | $1.00 | $3.24 | ||
| Q2 24 | $1.29 | $2.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $182.0M |
| 总债务越低越好 | $24.9B | — |
| 股东权益账面价值 | $22.7B | $2.9B |
| 总资产 | $59.0B | — |
| 负债/权益比越低杠杆越低 | 1.10× | — |
8季度趋势，按日历期对齐
现金及短期投资GILDR
| Q1 26 | — | $182.0M | ||
| Q4 25 | $68.0M | $198.0M | ||
| Q3 25 | $19.0M | $189.0M | ||
| Q2 25 | $69.0M | $180.0M | ||
| Q1 25 | — | $151.0M | ||
| Q4 24 | — | $154.0M | ||
| Q3 24 | — | $162.0M | ||
| Q2 24 | — | $164.0M |
总债务GILDR
| Q1 26 | — | — | ||
| Q4 25 | $24.9B | $6.8B | ||
| Q3 25 | $24.9B | $7.3B | ||
| Q2 25 | $24.9B | $7.0B | ||
| Q1 25 | $25.0B | $6.7B | ||
| Q4 24 | $26.7B | $6.7B | ||
| Q3 24 | $23.2B | $6.6B | ||
| Q2 24 | $23.3B | $6.5B |
股东权益GILDR
| Q1 26 | — | $2.9B | ||
| Q4 25 | $22.7B | $3.1B | ||
| Q3 25 | $21.5B | $3.1B | ||
| Q2 25 | $19.7B | $3.1B | ||
| Q1 25 | $19.2B | $3.0B | ||
| Q4 24 | $19.3B | $3.1B | ||
| Q3 24 | $18.5B | $3.1B | ||
| Q2 24 | $18.3B | $3.1B |
总资产GILDR
| Q1 26 | — | — | ||
| Q4 25 | $59.0B | $16.4B | ||
| Q3 25 | $58.5B | $16.5B | ||
| Q2 25 | $55.7B | $16.5B | ||
| Q1 25 | $56.4B | $16.4B | ||
| Q4 24 | $59.0B | $16.7B | ||
| Q3 24 | $54.5B | $16.5B | ||
| Q2 24 | $53.6B | $16.4B |
负债/权益比GILDR
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 2.24× | ||
| Q3 25 | 1.16× | 2.35× | ||
| Q2 25 | 1.27× | 2.27× | ||
| Q1 25 | 1.30× | 2.21× | ||
| Q4 24 | 1.38× | 2.14× | ||
| Q3 24 | 1.26× | 2.17× | ||
| Q2 24 | 1.28× | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $583.0M |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $273.0M |
| 自由现金流率自由现金流/营收 | 39.4% | 2.1% |
| 资本支出强度资本支出/营收 | 2.6% | 3.3% |
| 现金转化率经营现金流/净利润 | 1.52× | 6.27× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $595.0M |
8季度趋势，按日历期对齐
经营现金流GILDR
| Q1 26 | — | $583.0M | ||
| Q4 25 | $3.3B | $749.0M | ||
| Q3 25 | $4.1B | $442.0M | ||
| Q2 25 | $827.0M | $752.0M | ||
| Q1 25 | $1.8B | $651.0M | ||
| Q4 24 | $3.0B | $558.0M | ||
| Q3 24 | $4.3B | $629.0M | ||
| Q2 24 | $1.3B | $552.0M |
自由现金流GILDR
| Q1 26 | — | $273.0M | ||
| Q4 25 | $3.1B | $344.0M | ||
| Q3 25 | $4.0B | $-85.0M | ||
| Q2 25 | $720.0M | $63.0M | ||
| Q1 25 | $1.7B | $137.0M | ||
| Q4 24 | $2.8B | $-201.0M | ||
| Q3 24 | $4.2B | $30.0M | ||
| Q2 24 | $1.2B | $-87.0M |
自由现金流率GILDR
| Q1 26 | — | 2.1% | ||
| Q4 25 | 39.4% | 10.8% | ||
| Q3 25 | 51.0% | -2.7% | ||
| Q2 25 | 10.2% | 2.0% | ||
| Q1 25 | 24.8% | 4.4% | ||
| Q4 24 | 37.4% | -6.3% | ||
| Q3 24 | 55.2% | 0.9% | ||
| Q2 24 | 17.2% | -2.7% |
资本支出强度GILDR
| Q1 26 | — | 3.3% | ||
| Q4 25 | 2.6% | 12.8% | ||
| Q3 25 | 1.9% | 16.6% | ||
| Q2 25 | 1.5% | 21.6% | ||
| Q1 25 | 1.6% | 16.4% | ||
| Q4 24 | 1.9% | 23.8% | ||
| Q3 24 | 1.9% | 18.9% | ||
| Q2 24 | 1.9% | 20.1% |
现金转化率GILDR
| Q1 26 | — | 6.27× | ||
| Q4 25 | 1.52× | 5.67× | ||
| Q3 25 | 1.35× | 3.20× | ||
| Q2 25 | 0.42× | 5.74× | ||
| Q1 25 | 1.34× | 6.64× | ||
| Q4 24 | 1.67× | 4.13× | ||
| Q3 24 | 3.44× | 4.43× | ||
| Q2 24 | 0.82× | 4.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
R
暂无分部数据
